Actemra Is First Biologic Agent To Show Better Efficacy Than Methotrexate In RA

PARIS: The interleukin-6 receptor inhibitor Actemra (tocilizumab) achieves significantly greater reduction in the signs and symptoms of rheumatoid arthritis (RA) than the current standard of care, methotrexate, according to two international clinical trials reported this week at EULAR 2008, the Annual European Congress of Rheumatology.

Added: 18 июня 2008

Last relative articles:

Patients Taking Cymbalta reg; Reported Reduced Pain Severity Of Osteoarthritis Of The Knee In New Study
Joint Damage Is Inhibited With Enbrel reg; Etanercept Plus Methotrexate In Patients With Early Active Rheumatoid Arthritis
Cimzia reg; Is The First Anti-TNF Shown To Inhibit Progression Of Joint Damage As Early As 16 Weeks In Rheumatoid Arthritis
Novel DNA Microarray Chip Predicts Functional Impairment And Remission In Rheumatoid Arthritis
Oily Fish Can Protect Against RA, But Smoking And Psychosocial Stress Increase Its Risk
Specific Mutations In The IL2RA Gene Associated With Juvenile Idiopathic Arthritis
Rheumatoid Arthritis Is A Risk Factor For Cardiovascular Disease
In Risk Of Severe Cardiovascular Events, Rheumatoid Arthritis Factors Equal To Cardiovascular Factors
Recommendations For Rheumatoid Arthritis Therapy Presented By American College Of Rheumatology
Increased Incidence Of Melanoma Found In Rheumatoid Arthritis Patients Treated With Methotrexate

Comments: [0] / Post comment:

Keywords:

actemra, actemra biologic, ra actemra, actemra tocilizumab, inhibitor actemra

ALL NEWS TODAY © PoznaiSebya.Com
Designer Padayatra Dmytriy